An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services

Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to ma...

Full description

Saved in:
Bibliographic Details
Published inHarm reduction journal Vol. 14; no. 1; pp. 52 - 13
Main Authors Harper, Lane, Powell, Jeff, Pijl, Em M.
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 31.07.2017
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to make informed decisions. While these technologies have been used for years in Europe (Nightlife Empowerment & Well-being Implementation Project, Drug Checking Service: Good Practice Standards; Trans European Drugs Information (TEDI) Workgroup, Factsheet on Drug Checking in Europe, 2011; European Monitoring Centre for Drugs and Drug Addiction, An Inventory of On-site Pill-Testing Interventions in the EU: Fact Files, 2001), they are only now starting to be utilized in this context in North America. The goal of this paper is to describe the most common methods for testing illicit substances and then, based on this broad, encompassing review, recommend the most appropriate methods for testing at point of care.Based on our review, the best methods for point-of-care drug testing are handheld infrared spectroscopy, Raman spectroscopy, and ion mobility spectrometry; mass spectrometry is the current gold standard in forensic drug analysis. It would be prudent for agencies or clinics that can obtain the funding to contact the companies who produce these devices to discuss possible usage in a harm reduction setting. Lower tech options, such as spot/color tests and immunoassays, are limited in their use but affordable and easy to use.
AbstractList Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to make informed decisions. While these technologies have been used for years in Europe (Nightlife Empowerment & Well-being Implementation Project, Drug Checking Service: Good Practice Standards; Trans European Drugs Information (TEDI) Workgroup, Factsheet on Drug Checking in Europe, 2011; European Monitoring Centre for Drugs and Drug Addiction, An Inventory of On-site Pill-Testing Interventions in the EU: Fact Files, 2001), they are only now starting to be utilized in this context in North America. The goal of this paper is to describe the most common methods for testing illicit substances and then, based on this broad, encompassing review, recommend the most appropriate methods for testing at point of care.
Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to make informed decisions. While these technologies have been used for years in Europe (Nightlife Empowerment & Well-being Implementation Project, Drug Checking Service: Good Practice Standards; Trans European Drugs Information (TEDI) Workgroup, Factsheet on Drug Checking in Europe, 2011; European Monitoring Centre for Drugs and Drug Addiction, An Inventory of On-site Pill-Testing Interventions in the EU: Fact Files, 2001), they are only now starting to be utilized in this context in North America. The goal of this paper is to describe the most common methods for testing illicit substances and then, based on this broad, encompassing review, recommend the most appropriate methods for testing at point of care. Based on our review, the best methods for point-of-care drug testing are handheld infrared spectroscopy, Raman spectroscopy, and ion mobility spectrometry; mass spectrometry is the current gold standard in forensic drug analysis. It would be prudent for agencies or clinics that can obtain the funding to contact the companies who produce these devices to discuss possible usage in a harm reduction setting. Lower tech options, such as spot/color tests and immunoassays, are limited in their use but affordable and easy to use.
Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to make informed decisions. While these technologies have been used for years in Europe (Nightlife Empowerment & Well-being Implementation Project, Drug Checking Service: Good Practice Standards; Trans European Drugs Information (TEDI) Workgroup, Factsheet on Drug Checking in Europe, 2011; European Monitoring Centre for Drugs and Drug Addiction, An Inventory of On-site Pill-Testing Interventions in the EU: Fact Files, 2001), they are only now starting to be utilized in this context in North America. The goal of this paper is to describe the most common methods for testing illicit substances and then, based on this broad, encompassing review, recommend the most appropriate methods for testing at point of care. Based on our review, the best methods for point-of-care drug testing are handheld infrared spectroscopy, Raman spectroscopy, and ion mobility spectrometry; mass spectrometry is the current gold standard in forensic drug analysis. It would be prudent for agencies or clinics that can obtain the funding to contact the companies who produce these devices to discuss possible usage in a harm reduction setting. Lower tech options, such as spot/color tests and immunoassays, are limited in their use but affordable and easy to use. Keywords: Harm reduction, Substance abuse, Street drugs, Drug overdose, Drug users, Drug effects, Drug-related side effects and adverse reactions, Drug evaluation
Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to make informed decisions. While these technologies have been used for years in Europe (Nightlife Empowerment & Well-being Implementation Project, Drug Checking Service: Good Practice Standards; Trans European Drugs Information (TEDI) Workgroup, Factsheet on Drug Checking in Europe, 2011; European Monitoring Centre for Drugs and Drug Addiction, An Inventory of On-site Pill-Testing Interventions in the EU: Fact Files, 2001), they are only now starting to be utilized in this context in North America. The goal of this paper is to describe the most common methods for testing illicit substances and then, based on this broad, encompassing review, recommend the most appropriate methods for testing at point of care.Based on our review, the best methods for point-of-care drug testing are handheld infrared spectroscopy, Raman spectroscopy, and ion mobility spectrometry; mass spectrometry is the current gold standard in forensic drug analysis. It would be prudent for agencies or clinics that can obtain the funding to contact the companies who produce these devices to discuss possible usage in a harm reduction setting. Lower tech options, such as spot/color tests and immunoassays, are limited in their use but affordable and easy to use.
Abstract Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to make informed decisions. While these technologies have been used for years in Europe (Nightlife Empowerment & Well-being Implementation Project, Drug Checking Service: Good Practice Standards; Trans European Drugs Information (TEDI) Workgroup, Factsheet on Drug Checking in Europe, 2011; European Monitoring Centre for Drugs and Drug Addiction, An Inventory of On-site Pill-Testing Interventions in the EU: Fact Files, 2001), they are only now starting to be utilized in this context in North America. The goal of this paper is to describe the most common methods for testing illicit substances and then, based on this broad, encompassing review, recommend the most appropriate methods for testing at point of care. Based on our review, the best methods for point-of-care drug testing are handheld infrared spectroscopy, Raman spectroscopy, and ion mobility spectrometry; mass spectrometry is the current gold standard in forensic drug analysis. It would be prudent for agencies or clinics that can obtain the funding to contact the companies who produce these devices to discuss possible usage in a harm reduction setting. Lower tech options, such as spot/color tests and immunoassays, are limited in their use but affordable and easy to use.
Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to make informed decisions. While these technologies have been used for years in Europe (Nightlife Empowerment & Well-being Implementation Project, Drug Checking Service: Good Practice Standards; Trans European Drugs Information (TEDI) Workgroup, Factsheet on Drug Checking in Europe, 2011; European Monitoring Centre for Drugs and Drug Addiction, An Inventory of On-site Pill-Testing Interventions in the EU: Fact Files, 2001), they are only now starting to be utilized in this context in North America. The goal of this paper is to describe the most common methods for testing illicit substances and then, based on this broad, encompassing review, recommend the most appropriate methods for testing at point of care.Based on our review, the best methods for point-of-care drug testing are handheld infrared spectroscopy, Raman spectroscopy, and ion mobility spectrometry; mass spectrometry is the current gold standard in forensic drug analysis. It would be prudent for agencies or clinics that can obtain the funding to contact the companies who produce these devices to discuss possible usage in a harm reduction setting. Lower tech options, such as spot/color tests and immunoassays, are limited in their use but affordable and easy to use.Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction agencies are exploring techniques to test illicit drugs to identify and, where possible, quantify their constituents allowing their users to make informed decisions. While these technologies have been used for years in Europe (Nightlife Empowerment & Well-being Implementation Project, Drug Checking Service: Good Practice Standards; Trans European Drugs Information (TEDI) Workgroup, Factsheet on Drug Checking in Europe, 2011; European Monitoring Centre for Drugs and Drug Addiction, An Inventory of On-site Pill-Testing Interventions in the EU: Fact Files, 2001), they are only now starting to be utilized in this context in North America. The goal of this paper is to describe the most common methods for testing illicit substances and then, based on this broad, encompassing review, recommend the most appropriate methods for testing at point of care.Based on our review, the best methods for point-of-care drug testing are handheld infrared spectroscopy, Raman spectroscopy, and ion mobility spectrometry; mass spectrometry is the current gold standard in forensic drug analysis. It would be prudent for agencies or clinics that can obtain the funding to contact the companies who produce these devices to discuss possible usage in a harm reduction setting. Lower tech options, such as spot/color tests and immunoassays, are limited in their use but affordable and easy to use.
ArticleNumber 52
Audience Academic
Author Harper, Lane
Pijl, Em M.
Powell, Jeff
Author_xml – sequence: 1
  givenname: Lane
  surname: Harper
  fullname: Harper, Lane
– sequence: 2
  givenname: Jeff
  surname: Powell
  fullname: Powell, Jeff
– sequence: 3
  givenname: Em M.
  surname: Pijl
  fullname: Pijl, Em M.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28760153$$D View this record in MEDLINE/PubMed
BookMark eNp9kl1rHCEUhoeS0ny0P6A3RehNbybVUcfxprCEfgQCvWmvxdHjrsuMbnVmQ_59nWyaZkMpIsrxeV898p5XJyEGqKq3BF8S0rUfM2kkZzUmYpmy5i-qM8KEqAUn4uTJ_rQ6z3mLccFp96o6bTrRYsLpWTWsAop7SHsPtyg65GKCkL1BNs1rNEGefFijEaZNtBnpYNG0AZ9Qnv2kez_46W7RoI1OI0pgZzP5GNAu-jDV0dVGJ0B58TeQX1cvnR4yvHlYL6qfXz7_uPpW33z_en21uqkNb_FUOyO0ZaynBEOjOyKhY9I1DlrdgWxEjwHbTjfUOm1bjkUvKZSqYU4bITW9qK4PvjbqrdolP-p0p6L26r4Q01rpNHkzgNK4xR0Ax8Zy1nLWtdpQzjjvHW84W7w-Hbx2cz-CNRCmpIcj0-OT4DdqHfeKcyqkbIvBhweDFH_N5UPV6LOBYdAB4pwVkQ1vBGWCFvT9M3Qb5xTKV91TkmJO2r_UWpcGfHCx3GsWU7XihDSLlSzU5T-oMiyM3pQcOV_qR4J3Txt97PBPVgpADoBJMecE7hEhWC15VIc8qpLFZUrFi0Y805iSmyUi5TV--I_yN-uC5Gg
CitedBy_id crossref_primary_10_1002_dta_2750
crossref_primary_10_1108_DHS_12_2022_066
crossref_primary_10_3390_chemosensors12040058
crossref_primary_10_1111_dar_13237
crossref_primary_10_1111_imj_14742
crossref_primary_10_1016_j_socscimed_2022_115229
crossref_primary_10_1186_s12954_023_00882_y
crossref_primary_10_1186_s13011_023_00590_7
crossref_primary_10_1016_j_aca_2019_12_051
crossref_primary_10_3390_bs10080121
crossref_primary_10_1371_journal_pone_0288656
crossref_primary_10_1016_j_bios_2021_113002
crossref_primary_10_1016_j_drugalcdep_2023_111028
crossref_primary_10_1002_wfs2_1455
crossref_primary_10_1039_C8AN02464B
crossref_primary_10_1016_j_fsigen_2021_102559
crossref_primary_10_1021_acsami_3c03722
crossref_primary_10_1108_DHS_10_2022_0035
crossref_primary_10_1111_dar_13004
crossref_primary_10_1371_journal_pone_0292812
crossref_primary_10_1016_j_rinp_2019_102680
crossref_primary_10_1016_j_drugalcdep_2020_108006
crossref_primary_10_1111_dar_13370
crossref_primary_10_1186_s13011_018_0156_3
crossref_primary_10_1016_j_forc_2023_100475
crossref_primary_10_1039_D4LC00223G
crossref_primary_10_1016_j_procbio_2021_12_021
crossref_primary_10_1021_acsomega_4c08614
crossref_primary_10_1002_wfs2_1461
crossref_primary_10_1016_j_snb_2024_137215
crossref_primary_10_1111_dar_13816
crossref_primary_10_1002_dta_3022
crossref_primary_10_1080_10408347_2020_1802219
crossref_primary_10_3390_s22103877
crossref_primary_10_1002_dta_2973
crossref_primary_10_1109_TBCAS_2024_3405815
crossref_primary_10_33084_bjop_v4i2_1978
crossref_primary_10_1097_PHH_0000000000001581
crossref_primary_10_1016_j_ejpb_2022_08_017
crossref_primary_10_1016_j_talanta_2020_120987
crossref_primary_10_1016_j_drugalcdep_2017_12_026
crossref_primary_10_1177_0033354920915439
crossref_primary_10_1007_s00216_022_03924_9
crossref_primary_10_1007_s11030_021_10289_1
crossref_primary_10_3390_bios10030022
crossref_primary_10_1016_j_forc_2023_100489
crossref_primary_10_1111_dar_13829
crossref_primary_10_1007_s10404_023_02674_z
crossref_primary_10_1007_s00216_021_03670_4
crossref_primary_10_1016_j_jmr_2021_107138
crossref_primary_10_3389_fpubh_2022_983663
crossref_primary_10_1016_j_drugpo_2021_103409
crossref_primary_10_1111_dar_13825
crossref_primary_10_1016_j_forsciint_2019_110135
crossref_primary_10_1016_j_forc_2021_100331
crossref_primary_10_1002_jrs_6133
crossref_primary_10_1007_s12088_024_01303_9
crossref_primary_10_1016_j_drugpo_2024_104560
crossref_primary_10_1016_j_chroma_2023_463980
crossref_primary_10_1021_jasms_0c00295
crossref_primary_10_1002_ange_201910177
crossref_primary_10_1016_j_jelechem_2021_114994
crossref_primary_10_12998_wjcc_v11_i21_4996
crossref_primary_10_1016_j_drugpo_2018_08_007
crossref_primary_10_1016_j_drugalcdep_2019_01_045
crossref_primary_10_1002_wfs2_1371
crossref_primary_10_1016_j_drugalcdep_2021_108976
crossref_primary_10_1039_D0AN01246G
crossref_primary_10_1186_s40814_023_01321_2
crossref_primary_10_1016_j_dadr_2024_100247
crossref_primary_10_3390_s23135856
crossref_primary_10_1007_s00216_020_02571_2
crossref_primary_10_1016_j_chemolab_2021_104265
crossref_primary_10_1016_j_talanta_2022_123264
crossref_primary_10_1080_09687637_2024_2330938
crossref_primary_10_1186_s12954_024_01004_y
crossref_primary_10_1186_s12954_021_00478_4
crossref_primary_10_1186_s12954_023_00856_0
crossref_primary_10_1016_j_drugalcdep_2019_01_035
crossref_primary_10_1016_j_talanta_2022_123945
crossref_primary_10_1021_acs_analchem_9b00507
crossref_primary_10_1021_jasms_0c00112
crossref_primary_10_1016_j_drugpo_2019_06_018
crossref_primary_10_1016_j_electacta_2023_142009
crossref_primary_10_1016_j_snb_2022_132923
crossref_primary_10_1016_j_drugpo_2023_104086
crossref_primary_10_1016_j_jpba_2022_114728
crossref_primary_10_1016_j_scijus_2018_11_006
crossref_primary_10_1186_s12954_018_0276_0
crossref_primary_10_1007_s00216_022_04274_2
crossref_primary_10_1055_a_2167_2177
crossref_primary_10_1080_03067319_2023_2261008
crossref_primary_10_1080_08897077_2019_1616245
crossref_primary_10_1016_j_drugpo_2018_10_001
crossref_primary_10_1039_D2SD00043A
crossref_primary_10_1111_add_15734
crossref_primary_10_1021_jasms_1c00232
crossref_primary_10_3389_ijph_2023_1605955
crossref_primary_10_15406_frcij_2024_13_00433
crossref_primary_10_1016_j_jsat_2021_108418
crossref_primary_10_1016_j_forc_2021_100363
crossref_primary_10_1016_j_forc_2022_100443
crossref_primary_10_1016_j_talanta_2018_12_095
crossref_primary_10_1016_j_drugalcdep_2018_10_017
crossref_primary_10_1016_j_jpba_2022_114950
crossref_primary_10_1080_02791072_2022_2028203
crossref_primary_10_1002_rcm_9179
crossref_primary_10_1080_00952990_2023_2226312
crossref_primary_10_1016_j_drugalcdep_2018_11_033
crossref_primary_10_1021_acs_analchem_9b00176
crossref_primary_10_1016_j_vibspec_2023_103567
crossref_primary_10_1186_s12954_023_00921_8
crossref_primary_10_3389_fpsyt_2021_596895
crossref_primary_10_1515_revac_2022_0046
crossref_primary_10_1111_dar_13909
crossref_primary_10_1016_j_toxac_2025_01_094
crossref_primary_10_1186_s12954_024_00937_8
crossref_primary_10_1016_j_trac_2022_116828
crossref_primary_10_1016_j_forc_2021_100370
crossref_primary_10_1021_acs_analchem_2c01630
crossref_primary_10_1016_j_chemolab_2022_104574
crossref_primary_10_1016_j_drugalcdep_2025_112631
crossref_primary_10_1007_s00216_019_01644_1
crossref_primary_10_1038_s41598_020_60824_7
crossref_primary_10_1186_s12954_024_01014_w
crossref_primary_10_3390_chemosensors10030108
crossref_primary_10_1149_1945_7111_ac6c4f
crossref_primary_10_1016_j_scijus_2022_12_006
crossref_primary_10_1016_j_drugalcdep_2020_108416
crossref_primary_10_1002_pam_22048
crossref_primary_10_1186_s12954_018_0252_8
crossref_primary_10_3390_ijerph20115999
crossref_primary_10_1016_j_trac_2021_116447
crossref_primary_10_1039_D2AN01856J
crossref_primary_10_1016_j_ab_2020_113619
crossref_primary_10_1016_j_drugpo_2019_09_017
crossref_primary_10_1063_5_0046281
crossref_primary_10_1016_j_talanta_2024_126217
crossref_primary_10_1371_journal_pone_0274401
crossref_primary_10_1038_s43856_024_00642_4
crossref_primary_10_1097_PHH_0000000000002061
crossref_primary_10_1016_j_drugpo_2023_104206
crossref_primary_10_1080_10408347_2020_1785837
crossref_primary_10_3390_mps3020043
crossref_primary_10_1016_j_forc_2024_100572
crossref_primary_10_1111_1468_0009_12470
crossref_primary_10_15446_rev_colomb_quim_v52n1_108752
crossref_primary_10_1016_j_disamonth_2024_101851
crossref_primary_10_2139_ssrn_3997566
crossref_primary_10_1016_j_saa_2022_121684
crossref_primary_10_1186_s12954_021_00585_2
crossref_primary_10_3390_molecules26216713
crossref_primary_10_1016_j_japh_2023_12_015
crossref_primary_10_1186_s12954_024_01098_4
crossref_primary_10_1016_j_snb_2023_133766
crossref_primary_10_2105_AJPH_2017_304270
crossref_primary_10_1002_jrs_6520
crossref_primary_10_1002_mrc_5156
crossref_primary_10_1002_anie_201910177
crossref_primary_10_1016_j_talo_2022_100114
crossref_primary_10_1186_s13063_020_04898_8
crossref_primary_10_1177_29767342231212787
crossref_primary_10_1186_s12954_023_00836_4
crossref_primary_10_1016_j_drugpo_2020_102661
crossref_primary_10_31412_rbcp_v14i11_972
crossref_primary_10_1111_1556_4029_14437
crossref_primary_10_1177_10406387211070539
crossref_primary_10_1186_s12954_023_00764_3
crossref_primary_10_1016_j_snb_2021_131274
crossref_primary_10_1002_smll_202104847
crossref_primary_10_1080_08839514_2021_1966882
crossref_primary_10_1111_1556_4029_14318
crossref_primary_10_1039_D3RA06931A
crossref_primary_10_1080_00387010_2018_1501703
crossref_primary_10_1007_s11292_024_09643_8
crossref_primary_10_1016_j_drugpo_2020_102845
crossref_primary_10_3390_ijerph20064793
crossref_primary_10_3390_psychoactives2010001
crossref_primary_10_1021_acsomega_9b00302
crossref_primary_10_1080_10408347_2021_1958196
crossref_primary_10_1155_2020_8869713
crossref_primary_10_1016_j_drugpo_2020_102973
crossref_primary_10_1007_s00764_024_00319_7
crossref_primary_10_1016_j_chroma_2023_464097
crossref_primary_10_1016_j_snb_2019_04_053
crossref_primary_10_1111_imj_14258
crossref_primary_10_1002_dta_2605
crossref_primary_10_2139_ssrn_3397354
crossref_primary_10_1364_AO_423466
crossref_primary_10_1021_acschemneuro_1c00498
crossref_primary_10_1111_dar_12882
crossref_primary_10_1021_jasms_2c00090
crossref_primary_10_1016_j_jpba_2019_03_063
crossref_primary_10_1016_j_cll_2025_01_005
crossref_primary_10_1021_acssuschemeng_3c03517
crossref_primary_10_3390_s23063140
crossref_primary_10_1016_j_forsciint_2022_111277
crossref_primary_10_1177_00037028231160565
crossref_primary_10_1111_dar_12887
crossref_primary_10_3390_s23136201
crossref_primary_10_1002_elan_12034
crossref_primary_10_1016_j_addbeh_2020_106529
crossref_primary_10_1186_s12954_019_0336_0
crossref_primary_10_3389_fceng_2022_1112876
crossref_primary_10_1108_DHS_07_2022_0026
crossref_primary_10_1146_annurev_anchem_061020_124221
crossref_primary_10_1080_10826076_2024_2448692
crossref_primary_10_1016_j_forsciint_2020_110498
crossref_primary_10_1080_10826084_2020_1753773
crossref_primary_10_3390_ijerph191911960
crossref_primary_10_1080_10826084_2023_2231067
crossref_primary_10_1149_1945_7111_abba8f
crossref_primary_10_1016_j_snb_2020_129303
crossref_primary_10_1007_s00604_021_04851_9
crossref_primary_10_1016_j_drugpo_2021_103334
crossref_primary_10_1016_j_forsciint_2018_05_001
crossref_primary_10_1016_j_drugpo_2020_103037
crossref_primary_10_1021_acs_analchem_1c04512
crossref_primary_10_1016_j_saa_2021_120819
crossref_primary_10_1108_DHS_01_2022_0007
crossref_primary_10_1136_bmjopen_2023_076111
Cites_doi 10.1016/S0731-7085(96)01939-5
10.1002/dta.1969
10.1016/S0379-0738(99)00235-2
10.5694/mja15.01058
10.1111/add.13056
10.1007/3-540-29623-9_5050
10.1002/dta.1954
10.1039/B906433H
10.1002/jrs.4864
10.3109/15563658608992606
10.1002/jrs.1250201108
10.1080/00387011003601044
10.1016/j.forsciint.2013.07.012
10.1016/j.forc.2017.04.001
10.1081/SL-120038765
10.1039/c2an15953h
10.1016/j.forsciint.2010.08.005
10.1007/s11419-008-0041-2
10.1080/05704928.2011.625748
10.1002/dta.1949
ContentType Journal Article
Copyright COPYRIGHT 2017 BioMed Central Ltd.
Copyright BioMed Central 2017
The Author(s). 2017
Copyright_xml – notice: COPYRIGHT 2017 BioMed Central Ltd.
– notice: Copyright BioMed Central 2017
– notice: The Author(s). 2017
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
ATCPS
AZQEC
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
M0S
M1P
PATMY
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PYCSY
7X8
5PM
DOA
DOI 10.1186/s12954-017-0179-5
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability (subscription)
ProQuest Central
Agricultural & Environmental Science Collection
ProQuest Central Essentials
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Proquest Medical Database
Environmental Science Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Open Access Content Collection
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Environmental Science Collection
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Agricultural & Environmental Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Environmental Science Collection
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Environmental Science Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList


MEDLINE

MEDLINE - Academic
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Social Welfare & Social Work
EISSN 1477-7517
EndPage 13
ExternalDocumentID oai_doaj_org_article_a0608ee50cd5465486ac35455bf5254a
PMC5537996
A511234739
28760153
10_1186_s12954_017_0179_5
Genre Journal Article
Review
GeographicLocations Canada
GeographicLocations_xml – name: Canada
GroupedDBID ---
0R~
29I
2WC
2XV
53G
5GY
5VS
7X7
7XC
88E
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABIVO
ABUWG
ACGFO
ACGFS
ACHQT
ACIHN
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
ATCPS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EJD
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HCIFZ
HMCUK
HYE
IAO
IHR
INH
INR
IPY
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PATMY
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PYCSY
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7XB
8FK
AHSBF
AZQEC
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c560t-fc7ad44b310e2a819e849f2fe6a8e927b0e0d8a23dfad6507b93e7b0c4fac79a3
IEDL.DBID M48
ISSN 1477-7517
IngestDate Wed Aug 27 01:09:10 EDT 2025
Thu Aug 21 18:30:57 EDT 2025
Thu Jul 10 18:00:41 EDT 2025
Fri Jul 25 21:27:10 EDT 2025
Tue Jun 17 21:47:41 EDT 2025
Tue Jun 10 20:08:22 EDT 2025
Mon Jul 21 05:49:03 EDT 2025
Tue Jul 01 00:46:55 EDT 2025
Thu Apr 24 23:01:36 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Drug users
Drug-related side effects and adverse reactions
Drug effects
Drug evaluation
Harm reduction
Substance abuse
Drug overdose
Street drugs
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c560t-fc7ad44b310e2a819e849f2fe6a8e927b0e0d8a23dfad6507b93e7b0c4fac79a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
OpenAccessLink https://www.proquest.com/docview/1925930516?pq-origsite=%requestingapplication%
PMID 28760153
PQID 1925930516
PQPubID 105462
PageCount 13
ParticipantIDs doaj_primary_oai_doaj_org_article_a0608ee50cd5465486ac35455bf5254a
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5537996
proquest_miscellaneous_1925273473
proquest_journals_1925930516
gale_infotracmisc_A511234739
gale_infotracacademiconefile_A511234739
pubmed_primary_28760153
crossref_primary_10_1186_s12954_017_0179_5
crossref_citationtrail_10_1186_s12954_017_0179_5
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-07-31
PublicationDateYYYYMMDD 2017-07-31
PublicationDate_xml – month: 07
  year: 2017
  text: 2017-07-31
  day: 31
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Harm reduction journal
PublicationTitleAlternate Harm Reduct J
PublicationYear 2017
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References YS Manimala (179_CR20) 2016; 5
CAF Oliveira Penido de (179_CR26) 2016; 47
179_CR3
Q Li (179_CR41) 2012; 137
N Forsgard (179_CR19) 2010; 25
DF Rendle (179_CR31) 2003; 19
JK Brown (179_CR9) 1973; 13
JR Verkouteren (179_CR21) 2011; 206
D Sorak (179_CR25) 2012; 47
TM Brunt (179_CR16) 2017; 9
AA Bunaciu (179_CR23) 2010; 45
179_CR14
179_CR15
E Sisco (179_CR22) 2017; 4
Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG) (179_CR24) 2006
CM Hodges (179_CR28) 1989; 20
RA Engh (179_CR30) 2006
179_CR35
D Trzybiński (179_CR32) 2013; 232
EC Klatt (179_CR10) 1986; 24
RJ Butterfield (179_CR7) 2016; 204
Canadian Community Epidemiology Network on Drug Use (179_CR1) 2015
Standing Committee on Health (179_CR13) 2016
NV Phadnis (179_CR33) 1997; 15
CL O’Neal (179_CR37) 2000; 109
KM Elkins (179_CR38) 2017; 9
J Mounteney (179_CR4) 2016; 111
JA Marshman (179_CR11) 1974
C Sage (179_CR12) 2016
MP Elie (179_CR34) 2009
Canadian Institute for Health Information (179_CR2) 2016
RB Cody (179_CR18) 2005; 40
EMA Ali (179_CR27) 2017; 9
Trans European Drugs Information (TEDI) Workgroup (179_CR5) 2011
European Monitoring Centre for Drugs and Drug Addiction (179_CR6) 2001
K Kanai (179_CR36) 2008; 26
KA Frederick (179_CR29) 2004; 37
179_CR40
W Tregoning (179_CR8) 2016
JSC Tsai (179_CR17) 2005
A Dasgupta (179_CR39) 2009
References_xml – start-page: 471
  volume-title: Encyclopedia of analytical chemistry
  year: 2009
  ident: 179_CR34
– volume: 15
  start-page: 929
  issue: 7
  year: 1997
  ident: 179_CR33
  publication-title: J Pharm Biomed Anal
  doi: 10.1016/S0731-7085(96)01939-5
– volume: 13
  start-page: 670
  issue: 12
  year: 1973
  ident: 179_CR9
  publication-title: J Am Pharm Assoc
– volume: 9
  start-page: 256
  issue: 2
  year: 2017
  ident: 179_CR27
  publication-title: Drug Test Anal
  doi: 10.1002/dta.1969
– volume: 109
  start-page: 189
  issue: 3
  year: 2000
  ident: 179_CR37
  publication-title: Forensic Sci Int
  doi: 10.1016/S0379-0738(99)00235-2
– volume: 204
  start-page: 144
  issue: 4
  year: 2016
  ident: 179_CR7
  publication-title: Med J Aust
  doi: 10.5694/mja15.01058
– volume-title: Executive Agency for Health and Consumers
  year: 2011
  ident: 179_CR5
– volume-title: An inventory of on-site pill-testing interventions in the EU: fact files
  year: 2001
  ident: 179_CR6
– volume: 111
  start-page: 34
  issue: 1
  year: 2016
  ident: 179_CR4
  publication-title: Addiction
  doi: 10.1111/add.13056
– ident: 179_CR15
– start-page: 2026
  volume-title: Encyclopedic reference of genomics and proteomics in molecular medicine
  year: 2006
  ident: 179_CR30
  doi: 10.1007/3-540-29623-9_5050
– volume-title: Drug checking at music festivals: a how-to guide
  year: 2016
  ident: 179_CR12
– start-page: 1242
  volume-title: Encyclopedia of analytical chemistry
  year: 2009
  ident: 179_CR39
– volume: 9
  start-page: 188
  issue: 2
  year: 2017
  ident: 179_CR16
  publication-title: Drug Test Anal
  doi: 10.1002/dta.1954
– volume: 25
  start-page: 74
  issue: 1
  year: 2010
  ident: 179_CR19
  publication-title: J Anal At Spectrom
  doi: 10.1039/B906433H
– volume: 47
  start-page: 28
  issue: 1
  year: 2016
  ident: 179_CR26
  publication-title: J Raman Spectrosc
  doi: 10.1002/jrs.4864
– ident: 179_CR3
– volume: 40
  start-page: 8
  issue: 1
  year: 2005
  ident: 179_CR18
  publication-title: JEOL News
– volume: 24
  start-page: 441
  issue: 5
  year: 1986
  ident: 179_CR10
  publication-title: J Toxicol Clin Toxicol
  doi: 10.3109/15563658608992606
– start-page: 29
  volume-title: Drug-testing technologies and applications
  year: 2005
  ident: 179_CR17
– volume: 20
  start-page: 745
  issue: 11
  year: 1989
  ident: 179_CR28
  publication-title: J Raman Spectrosc
  doi: 10.1002/jrs.1250201108
– volume-title: Street drug analysis and its social and clinical implications
  year: 1974
  ident: 179_CR11
– volume-title: Deaths involving fentanyl in Canada, 2009–2014
  year: 2015
  ident: 179_CR1
– volume: 45
  start-page: 206
  issue: 3
  year: 2010
  ident: 179_CR23
  publication-title: Appl Spectrosc Rev
  doi: 10.1080/00387011003601044
– volume-title: Hospitalizations and emergency department visits due to opioid poisoning in Canada
  year: 2016
  ident: 179_CR2
– volume-title: Drug checking services
  year: 2016
  ident: 179_CR8
– volume: 232
  start-page: e28
  issue: 1
  year: 2013
  ident: 179_CR32
  publication-title: Forensic Sci Int
  doi: 10.1016/j.forsciint.2013.07.012
– ident: 179_CR35
– volume: 4
  start-page: 108
  year: 2017
  ident: 179_CR22
  publication-title: Forensic Chemistry
  doi: 10.1016/j.forc.2017.04.001
– volume: 37
  start-page: 301
  issue: 3
  year: 2004
  ident: 179_CR29
  publication-title: Spectrosc Lett
  doi: 10.1081/SL-120038765
– volume: 137
  start-page: 1596
  issue: 7
  year: 2012
  ident: 179_CR41
  publication-title: Analyst
  doi: 10.1039/c2an15953h
– volume: 5
  start-page: 118
  issue: 2
  year: 2016
  ident: 179_CR20
  publication-title: J Pharm Anal
– ident: 179_CR40
– volume-title: Supplemental document SD-2 for part IVB, quality assurance/validation of analytical methods
  year: 2006
  ident: 179_CR24
– ident: 179_CR14
– volume: 206
  start-page: 190
  issue: 1–3
  year: 2011
  ident: 179_CR21
  publication-title: Forensic Sci Int
  doi: 10.1016/j.forsciint.2010.08.005
– volume: 26
  start-page: 6
  issue: 1
  year: 2008
  ident: 179_CR36
  publication-title: Forensic Toxicol
  doi: 10.1007/s11419-008-0041-2
– volume: 47
  start-page: 83
  issue: 2
  year: 2012
  ident: 179_CR25
  publication-title: Appl Spectrosc Rev
  doi: 10.1080/05704928.2011.625748
– volume: 9
  start-page: 306
  issue: 2
  year: 2017
  ident: 179_CR38
  publication-title: Drug Test Anal
  doi: 10.1002/dta.1949
– volume-title: Vol. 42nd parliament, 1st session
  year: 2016
  ident: 179_CR13
– volume: 19
  start-page: 11
  issue: 2
  year: 2003
  ident: 179_CR31
  publication-title: Rigaku J
SSID ssj0029538
Score 2.5483632
SecondaryResourceType review_article
Snippet Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm reduction...
Abstract Given the current opioid crisis around the world, harm reduction agencies are seeking to help people who use drugs to do so more safely. Many harm...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 52
SubjectTerms Analysis
Analytical chemistry
Canada
Care and treatment
Color
Costs
Drug abuse
Drug addiction
Drug effects
Drug overdose
Drug testing
Drug users
Drugs
Empowerment
Encyclopedias
Forensic engineering
Forensic science
Forensic sciences
Fourier transforms
Harm Reduction
Humans
Identification
Immunoassays
Infrared spectroscopy
Ionic mobility
Laboratories
Legal medicine
Mass spectrometry
Mass spectroscopy
Methods
Music festivals
Opioids
Pharmaceutical Preparations - blood
Pharmaceutical Preparations - urine
Pharmaceuticals
Point of care testing
Point-of-Care Systems - legislation & jurisprudence
Raman spectroscopy
Reduction
Reproducibility of Results
Review
Scientific imaging
Street drugs
Substance abuse
Substance Abuse Detection - legislation & jurisprudence
Urine
Well being
Working groups
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Ji9RAFC5kTl7E3XZaKUEUhGKy1HpsxWHw4MnBuRWVWsbGJhmS9MF_73updNNB0IuHXGqBVNVbvpd6-R4hb4uqMaLhNYuxiozH5JiptGOAjFOpAi-jn9g-v8qra_7lRtyclPrCnLBMD5w37sIVstAxisIHrNvNtXS-BrcvmiQguJmgEfi8QzA1h1oG9Hi-wyy1vBhKvM5iaJFRAplYeKGJrP9Pk3zik5b5kicO6PIheTAjR7rJb_yI3IvtY7LOv9fS73GXXB_pO3po6PqfT8hu01LM0cTv_7RLFBAqJqx7Gvr9LR2RYaO9pbmK9EBdG-h0cUCH_XbMBN6_cA5FfmvaI8srniO967btyLrEMG-MDrO5eUquLz9_-3TF5voKzAPOGVnyygXOG0B4sXIADaLmJlUpSqejqVRTxCJoV9UhuQBITjWmjtDqeXJeGVc_I2dt18YXhHolpQ4KsIaXXHIDMCCVInFduCpUsl6R4rDf1s_k41gDY2enIERLm4_IwvHgY6xYkQ_HKXeZeeNvgz_iIR4HImn21ACiZGdRsv8SpRV5jyJgUbXh5byb_1CAJSJJlt0gOK25qs2KrBcjQSX9svsgRHY2CYMFKC0MWNdSrsibYzfOxDS3Nnb7PAb5hhRs2PMsc8clQWgLwbOAHrWQxsWalz3t9sdEGC5ErSCuffk_Numc3K8mPcLP22tyNvb7-Apw2di8nlTwN6FLNC4
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Jj9MwFLZguHBB7BQKMhICCcmaLF7iEyqI0YgDJ0b0ZjleSkWVlCQ98O95L3E7EyHNIRcvUpy3-Hv2y_cIeZcVtRY1L1kIRWA8RMt0UVkGyDjmyvM8uJHt87u8vOLf1mKdDtz6lFZ59Imjo_atwzPyc0AiQoNy5vLT_g_DqlF4u5pKaNwl95C6DFO61Po64NJgzekmM6_keZ_jpRZDv4x6yMRsLxop-_93zDd2pnnW5I1t6OIheZDwI11NAn9E7oTmMVlOP9nSn2EXbRfoe3psaLvfT8hu1VDM1MQV0jZSwKmYtu6o7w4bOiDPRrOhUy3pntrG0_H6gPaH7TDReP_FORRZrmmHXK8oTbpvt83A2sgwe4z2yek8JVcXX398uWSpygJzgHYGFp2ynvMacF4oLACEUHEdixikrYIuVJ2FzFe2KH20HvCcqnUZoNXxaJ3StnxGzpq2CS8IdUrKyitAHE5yyTWAgZiLyKvMFr6Q5YJkx-9tXKIgx0oYOzOGIpU0k4gMiAcfbcSCfDxN2U_8G7cN_oxCPA1E6uyxoe02JlmisZnMqhBE5jwWgueVtK4EHCnqKCBatgvyAVXAoIHDyzmb_lOAJSJVllkhRC25KvWCLGcjwTDdvPuoRCY5ht5cq_GCvD1140xMdmtCe5jGIOuQgg_2fNK505IgwIUQWkCPmmnjbM3znmb7a6QNF6JUEN2-vP21XpH7xWgheHy9JGdDdwivAXcN9ZvRuP4BszIsXw
  priority: 102
  providerName: ProQuest
Title An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services
URI https://www.ncbi.nlm.nih.gov/pubmed/28760153
https://www.proquest.com/docview/1925930516
https://www.proquest.com/docview/1925273473
https://pubmed.ncbi.nlm.nih.gov/PMC5537996
https://doaj.org/article/a0608ee50cd5465486ac35455bf5254a
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEA_38eKL-G11XSKIghDtRz7aB5E9ueMQPERc3LeQpsne4tKe3S54_70zaXe54iE-7EsyWZpkJvlNZ_obQl7FaVmIkmfMudQx7rxhRZobBsjYJ6riibOB7fNCns_554VYHJBdeathATe3unZYT2rert_9_nX9EQz-QzD4XL7fJBisYnjeon4xcUiO4WJSaKdf-D6oAEKhsHXClYJnSdQQ5Lz1L0bXVGDz__vMvnFpjRMqb9xQZ_fI3QFa0lmvC_fJgasfkEn__S394dbetI6-pruGpv35kKxnNcUkTgwQ0MZTgLCY0W5p1W6XtEMKjnpJ-zLTG2rqiobIAt1sV13P8H2NYygSYNMWaWBxo-lVs6o71niGiWV0M5xHj8j87PT7p3M2FGBgFoBQx7xVpuK8BAjoUgPYweW88Kl30uSuSFUZu7jKTZpV3lQA9VRZZA5aLffGqsJkj8lR3dTuKaFWSZlXCsCIlVzyAnCCT4TneWzSKpVZROLdems7sJNjkYy1Dl5KLnW_RRq2B3-FFhF5ux9y1VNz_Ev4BDdxL4is2qGhaZd6MFJtYhnnzonYVlgjnufS2Awgpii9AEfaROQNqoBGbYSHs2b4hAGmiCxaeoboNeMqKyIyGUmCzdpx906J9E7lNWBtUcDxm8iIvNx340jMg6tds-1lkJBIwYI96XVuPyXwfcG7FtCjRto4mvO4p15dBkZxITIFju-z_57fc3InDcaCL7kn5Khrt-4FoLOunJJDtVBTcnxyevH12zS845gGO_wDjJQ40g
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbK9gAXxJuFBYzEQ0KymjiOkxwQ2kKrLS0VQq3ozXUce1mxSpYkK9Q_xW9kJo-lEVJvPeTiRxTb45lv4vE3hLzyeJqEqQiYtdwyYZ1mCY81A2Ts_CgTvjUN2-exnJ2Kz2fh2Rb509-FwbDKXic2ijorDP4j3wEkEiYgnL78sPrFMGsUnq72KTRasTi0F7_BZaveH3yC9X3N-f7eyccZ67IKMAPWvWbORDoTIgVcY7kGg2hjkTjurNSxTXiUetbLYs2DzOkM8EuUJoGFUiOcNlGiA3jvDbItAnBlRmR7d-_467eNi5eA_ujOTv1Y7lQ-HqMxtAQo-SwcWL8mScD_puCSLRzGaV4yfPt3yO0OsdJpK2J3yZbN75FJe62XfrdLp0tL39C-oCh_3ifLaU4xNhTnlBaOAjLGQHlDs3I9pzUye-Rz2mavrqjOM9ocWNBqvahb4vAL7EORV5uWyC6L8kNXxSKvWeEYxqvRqlNzD8jptazAQzLKi9w-JtREUsZZBBjHSCFFAvDD-aETsad5xmUwJl4_38p0pOeYe2OpGucnlqpdIgXLg0-iwjF5t-myahk_rmq8i4u4aYhk3U1BUc5Vt_eV9qQXWxt6JsPU8yKW2gSAXMPUheCf6zF5iyKgUKXAxxnd3YyAISI5l5oiKA5EFCRjMhm0BFVghtW9EKlOFVXq38YZk5ebauyJ4XW5LdZtG-Q5imDCHrUytxkSuNQg6SHURANpHIx5WJMvfjRE5WEYROBPP7n6s16Qm7OTL0fq6OD48Cm5xZvdgj_PJ2RUl2v7DFBfnT7vthol59e9u_8C_J1sSA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+overview+of+forensic+drug+testing+methods+and+their+suitability+for+harm+reduction+point-of-care+services&rft.jtitle=Harm+reduction+journal&rft.au=Harper%2C+Lane&rft.au=Powell%2C+Jeff&rft.au=Pijl%2C+Em+M&rft.date=2017-07-31&rft.pub=BioMed+Central+Ltd&rft.issn=1477-7517&rft.eissn=1477-7517&rft.volume=14&rft.issue=1&rft_id=info:doi/10.1186%2Fs12954-017-0179-5&rft.externalDocID=A511234739
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-7517&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-7517&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-7517&client=summon